Adaptimmune received U.S. FDA accelerated approval of Tecelra® (afami-cel), the first approved engineered cell therapy for a solid tumor
Patients can begin treatment journey; biomarker testing available; Adaptimmune systems ready to receive orders
At the end of Q2, Adaptimmune had Total Liquidity[1] of $214.8 million
A live webcast and replay can be accessed HERE. Call in information is as follows: +1-844-763-8274 (US or Canada) or +1-647-484-8814 (International). Callers should dial in 5-10 minutes prior to the scheduled start time and simply ask to join the Adaptimmune call.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.